-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4427 A Retrospective Analysis on the Efficacy and Saftey of Obinutuzumab in the Treatment of Non-Hodgkin B Cell Lymphoma

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
drug development, Therapies
Monday, December 11, 2023, 6:00 PM-8:00 PM

Yangzhi Zhao, MD/PhD1*, Wei Guo1*, Jia Li1, Xingtong Wang, MD2, Xin Wan, MD1*, Junna Li, MD3* and Ou Bai, MD/PhD4*

1Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China
2Department of Hematology, The First Hospital of Jilin University, Changchun, KY, China
3Department of Hematology, The first hospital of Jilin University, Changchun, Jilin, China
4The First Hospital of Jilin University, Changchun, Jilin, China

Backgroud: Obinutuzumab was approved by China’s Drug Administration in June 2021, and there have been few real-world reports about efficacy and safety.

Objective: Analysis the efficacy and safety of Obinutuzumab in the treatment of non-Hodgkin B cell lymphoma in our center.

MethodsWe analysed the non-Hodgkin B cell lymphoma patients who received Obinutuzumab combined with chemotherapy or maintenance treatment during September 2021 and July 2023, median follow up 9 months(1-20), to evaluate efficacy and safety.

Results: In all 165 patients, male 88(53%), female 77(47%), median 56 (26-83) years. FL 80 (48%), MZL 22 (13%), CLL/SLL 13 (8%), DLBCL 42 (25%), others 8 (5%). Newly diagnosed patients 114 (69%), relapsed/refractory 51 (31%). 124 patients received Obinutuzumab combined therapy, and 42 (25%) patients received Obinutuzumab maintenance treatment. Median treatment 4 cycles(1-11). I/II 33 (20 %), III/IV 131 (79 %). Low-medium group 91(55%), medium-high group 74(45%). ORR 66.7%, CRR 40.6%. 3 patients died of progression of disease. 1 elder patient died of pneumonia. Further subgroup analysis revealed, ORR(78% vs 22%, p<0.001)and CRR(81% vs 19%, p=0.02)of newly diagnosed patients were better than relapsed/refractory patients. There was no difference in CRR among different stages patients(I/II vs III/IV, 24% vs 76%, p=0.424), ORR(58% vs 42%, p=0.373)and CRR (63% vs 37%, p=0.481)between low-medium and medium-high patients. The patients received more than 4 cycles treatment with better ORR and CRR. The intensive treatment of Obinutuzumab in first cycle could improve ORR (87% vs 13%, p=0.036,)and decreased IgM ( p=0.0016), but didn’t not affect CRR (87% vs13%, p=0.343), IgG ( p=0.13) and IgA ( p=0.41). Maintenance treatment decreased IgM ( p=0.00064)but not for IgG or IgA. In treatment related side effects, any adverse events were 42(25%), more than grade III were 18(11%), tumor lysis syndrome 11 (7%), only one patient need blood purification treatment and recovered. Liver injury 8 (5%) . All the infusion-related response 23(14%)were grade I-II. Only 2 patients delayed treatment because of the side effects.

Conclusion: Obinutuzumab is safe and effective in the treatment of non-Hodgkin B cell lymphoma, even for the III/IV or medium-high group patients will have similar results with I/II or low-medium patients. Further follow-up is still needed to determine the long-time efficacy and safety.

Key words: retrospective analysis, Obinutuzumab, non-Hodgkin lymphoma.

Disclosures: No relevant conflicts of interest to declare.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH